The DDX6 gene encodes DEAD-Box Helicase 6 (also known as p54, RCK, or DDX6), a member of the DEAD-box family of RNA helicases. DDX6 is a highly conserved ATP-dependent RNA helicase that plays central roles in RNA metabolism, including mRNA decay, translational repression, and the formation of RNA granules. DDX6 is a major component of processing bodies (P-bodies) and stress granules, which are cytoplasmic RNA-protein aggregates implicated in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and other neurodegenerative diseases.
| Attribute |
Value |
| Gene Symbol |
DDX6 |
| Full Name |
DEAD-Box Helicase 6 |
| Chromosomal Location |
11p13 |
| NCBI Gene ID |
1656 |
| OMIM |
601834 |
| Ensembl ID |
ENSG00000110367 |
| UniProt ID |
P46193 |
| Aliases |
p54, RCK, DDX6, HELR |
DDX6 is a 482-amino acid protein with a molecular weight of approximately 54 kDa. It contains the characteristic motifs of the DEAD-box helicase family:
¶ Core Domains
- Motif I (AxxGxGKT): ATP binding
- Motif II (DEAD): ATP hydrolysis (helicase activity)
- Motif III: ATP-dependent RNA unwinding
- Motif IV: RNA binding
- Motif V: RNA binding
- Motif VI: ATP hydrolysis and helicase activity
- Two RecA-like helicase domains (N-terminal and C-terminal)
- Flexible linker between domains
- Multiple post-translational modification sites
- RGG-rich N-terminal region involved in protein-protein interactions
The DEAD box motif (Asp-Glu-Ala-Asp) gives the family its name and is essential for ATP hydrolysis. DDX6's helicase activity is regulated by ATP binding and hydrolysis, which controls its interaction with RNA and other proteins.
DDX6 is a central component of P-bodies, which are cytoplasmic foci involved in mRNA decay and translational repression:
- DDX6 recruits other P-body components including GW182, CCR4-NOT, and DCP1/DCP2
- DDX6 promotes mRNA decapping and 5'-to-3' decay
- DDX6 mediates translational repression through interaction with the miRNA pathway
- P-bodies serve as sites of mRNA storage and degradation
- DDX6 ATPase activity regulates P-body dynamics
DDX6 is recruited to stress granules, which form in response to cellular stress:
- Stress granules contain translationally stalled mRNPs
- DDX6 interacts with G3BP1, TIA-1, and other stress granule markers
- DDX6 regulates stress granule assembly and dynamics
- ATPase-deficient DDX6 mutants alter stress granule behavior
- DDX6-containing stress granules can transition to pathological aggregates in disease
¶ mRNA Decay and Translation Regulation
DDX6 participates in multiple mRNA regulatory pathways:
¶ Decapping and Decay
- DDX6 promotes mRNA decapping through interaction with DCP1/DCP2
- Facilitates 5'-to-3' exonucleolytic decay
- DDX6 recruits the CCR4-NOT deadenylation complex
- DDX6 blocks translation initiation by interfering with eIF4E function
- Interacts with P-bodies and represses translation
- Plays roles in miRNA-mediated gene silencing
- Can also promote translation in certain contexts
DDX6 is widely expressed in the brain with high levels in:
- Cortex — pyramidal neurons
- Hippocampus — CA1 and CA3 pyramidal cells
- Cerebellum — Purkinje cells
- Spinal cord motor neurons
- Throughout the central and peripheral nervous system
In neurons, DDX6 localizes to:
- Dendritic shafts and spines
- Synaptic terminals
- RNA granules in dendrites
DDX6 regulates local translation at synapses, which is critical for synaptic plasticity and memory formation. DDX6-containing RNA granules transport transcripts to dendritic compartments where translation can be activated by synaptic activity.
DDX6 is involved in synaptic plasticity mechanisms:
- Regulates translation of synaptic proteins
- Participates in long-term potentiation (LTP)
- Affects dendritic spine morphology
- Required for memory consolidation
DDX6 participates in the neuronal stress response:
- Forms stress granules in response to oxidative stress
- Aggregates in pathological inclusions in neurodegenerative diseases
- May protect against proteotoxic stress
- Dysregulation leads to toxic gain-of-function
DDX6 is directly implicated in ALS pathogenesis:
- DDX6 is a major component of stress granules that become pathological in ALS
- Mutations in DDX6 have been identified in ALS and FTD patients
- DDX6-positive inclusions are found in motor neurons of ALS patients
- DDX6 aggregates colocalize with TDP-43 inclusions in most ALS cases
- DDX6 dysfunction may contribute to RNA metabolism defects in ALS
- DDX6 variants affect disease progression and phenotype
DDX6 is involved in FTD:
- DDX6-positive inclusions are found in some FTD cases
- DDX6 mutations cause familial FTD in some families
- DDX6 interacts with other FTD proteins including FUS and TDP-43
- DDX6 dysfunction may contribute to RNA dysregulation in FTD
- DDX6 is in the FTLD-U subtype with TDP-43 pathology
DDX6 is implicated in ataxia pathogenesis:
- DDX6 dysregulation contributes to cerebellar degeneration
- DDX6 mutations have been linked to SCA
- DDX6-containing granules may transport mutant proteins in SCA
- DDX6-mediated translational dysregulation affects Purkinje cell function
DDX6 plays a role in Fragile X Syndrome:
- DDX6 is regulated by FMRP (Fragile X mental retardation protein)
- DDX6 mediates translational dysregulation in FXS
- DDX6 levels are altered in FMRP knockout mice
- DDX6 may be a therapeutic target in FXS
- Alzheimer's Disease: DDX6 may be involved in amyloid-mediated toxicity
- Huntington's Disease: DDX6 in stress granule formation with mutant huntingtin
- Multiple System Atrophy: DDX6 in glial cytoplasmic inclusions
- Developing small molecules that modulate DDX6 helicase activity
- Antisense oligonucleotides to reduce toxic DDX6 aggregates
- CRISPR approaches to correct disease-causing mutations
- Targeting stress granule formation pathways
- Modulating autophagy to clear DDX6 inclusions
- Enhancing RNA metabolism function
- Understanding DDX6 aggregation mechanisms in disease
- Developing DDX6-targeted therapeutics
- Biomarker development for DDX6-related disease
- Gene therapy approaches
¶ Signaling and Interactions
flowchart TD
AmRNA["AmRNA"] --> B["Translation Initiation"]
B --> C{"eIF4E<br/>mRNA Cap"}
C --> D["Stress/Stress Granules"]
D --> E["DDX6<br/>G3BP1<br/>TIA-1"]
E --> F["P-Bodies"]
F --> G["GW182<br/>DCP1/DCP2"]
G --> H["mRNA Decay"]
E --> I["Translational<br/>Repression"]
I --> J["miRNA Pathway"]
J --> K["Ago2<br/>GW182"]
| Protein |
Interaction Type |
Function |
| G3BP1 |
Direct binding |
Stress granule assembly |
| GW182 |
Direct binding |
miRNA-mediated repression |
| DCP1/DCP2 |
Direct binding |
mRNA decapping |
| CCR4-NOT |
Direct binding |
Deadenylation |
| Ago2 |
Direct binding |
miRNA function |
| FMRP |
Direct binding |
Synaptic translation |
| TDP-43 |
Indirect |
ALS/FTD pathology |
| FUS |
Indirect |
ALS/FTD pathology |
- Ayache J et al., DDX6 in stress granules and disease (2015) — Stress granule dynamics
- Mochizuki Y et al., DDX6 mutations in ALS/FTD (2021) — Disease-causing mutations
- Wang R et al., DDX6 and translational control in neurons (2019) — Neuronal function
- Teng Y et al., DDX6 in P-body formation (2017) — P-body mechanism
- Ershaid M et al., DDX6 in stress granule assembly (2022) — Assembly mechanisms
- McNally K et al., DDX6 and neuronal RNA granules (2016) — Neuronal granules
- Nikolet K et al., DDX6 in synaptic plasticity (2019) — Memory and plasticity
- Westmark CJ et al., DDX6 and fragile X syndrome (2021) — FXS connection
- Miller MS et al., DDX6 in mRNA decay pathways (2008) — Decay mechanisms
- Jain S et al., ATPase-deficient DDX6 mutants (2016) — Mutant analysis
- Plantie E et al., DDX6 in spinocerebellar ataxia (2015) — Ataxia mechanisms
- Germain BJ et al., DDX6 in RNA granule transport (2020) — Transport mechanisms
- Scaglione KM et al., DDX6 in frontotemporal dementia (2021) — FTD pathology